Exploring the Feasibility of a Bracketing Approach Utilizing Modeling for Development of Long-Acting Injectables for Regulatory Approval—A Case Study Using Levonorgestrel
Susan Cole, Henry Pertinez, Andrew S. Butler, Essam Kerwash, Swati Bhat, Eman El-Khateeb, Andrew Owen · 2024
Read Exploring the Feasibility of a Bracketing Approach Utilizing Modeling for Development of Long-Acting Injectables for Regulatory Approval—A Case Study Using Levonorgestrel by Susan Cole, Henry Pertinez, Andrew S. Butler, Essam Kerwash, Swati Bhat, Eman El-Khateeb, Andrew Owen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11677509.txt.
Description
Long-acting contraceptive injections free users from daily pills, but each new product normally needs fresh clinical trials. Susan Cole and co-authors explore a shortcut in a 2024 case study built on the hormone levonorgestrel. The idea is bracketing: if a new product keeps blood levels between a floor set by efficacy and a ceiling set by safety, regulators might accept modeling instead of new trials.
The team modeled trial data from three existing levonorgestrel products to pin down the floor. Levels around 200 to 400 picograms per milliliter marked the range tied to reliable contraception. The safety ceiling proved harder to define from the literature. European and United Kingdom regulatory records were checked for precedent. The authors judge the approach feasible but incomplete until the ceiling firms up.
Catalog record
| CREATOR | Susan Cole, Henry Pertinez, Andrew S. Butler, Essam Kerwash, Swati Bhat, Eman El-Khateeb, Andrew Owen |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |